A rare form of blood cancer disguised itself with an unusual genetic signature, forcing doctors to rethink how they diagnose and treat mast cell leukemia, the most severe form of systemic mastocytosis. In a case published in Frontiers in Oncology, an 81-year-old woman presented with back pain and dizziness, only to be diagnosed with a life-threatening immune disorder that required precision diagnostics to identify correctly.

What Is Mast Cell Leukemia and Why Does It Matter?

Mast cells are immune cells that normally help your body fight infections and manage inflammation. In systemic mastocytosis (SM), these cells multiply uncontrollably in the bone marrow and other tissues. Mast cell leukemia (MCL) is the most aggressive form, where abnormal mast cells flood the bloodstream and bone marrow. The condition is exceptionally rare, making it difficult for doctors to recognize and treat.

The patient in this case had severe blood abnormalities when she arrived at the hospital. Her hemoglobin, which carries oxygen in red blood cells, was dangerously low at 42 g/L (normal is around 120-160 g/L), and her platelets, which help with blood clotting, were critically reduced at 23 × 10^9/L (normal is 150-400 × 10^9/L). Despite these alarming findings, she lacked the typical warning signs doctors usually associate with systemic mastocytosis, such as an enlarged liver or spleen, or a characteristic rash.

How Did Doctors Finally Identify This Hidden Disease?

The breakthrough came through integrated, multimodal diagnostics that examined the patient's cells from multiple angles. Standard blood tests showed only 3% atypical mast cells circulating in her bloodstream, which initially seemed unremarkable. However, a bone marrow biopsy revealed the true extent of the disease: 69.5% of cells in the bone marrow were abnormal mast cells with unusual shapes and features.

The diagnostic workup included several specialized tests that painted a complete picture:

• Flow Cytometry: This test revealed an unusual immunophenotype, or immune cell profile, that deviated significantly from what doctors typically see in mast cell cancers. The cells were CD117 bright, CD9 bright, and CD203c positive, but notably lacked CD25, which is usually present in neoplastic mast cells.
• Cytogenetic Analysis: Chromosome testing showed a complex karyotype, including monosomy 7 (loss of one copy of chromosome 7), indicating high-risk disease biology and a more aggressive form of the cancer.
• Molecular Profiling: DNA sequencing uncovered a rare KIT p.V559G mutation with a 42% variant allele frequency, distinct from the canonical KIT p.D816V mutation commonly seen in systemic mastocytosis. This noncanonical mutation, located in the juxtamembrane domain of the KIT protein, appears linked to the CD25-negative immune profile the patient displayed.

The absence of other common mutations in genes like SRSF2, ASXL1, RUNX1, TET2, and NPM1 further emphasized how unique this patient's molecular profile was, making her case a valuable addition to medical knowledge about rare immune diseases.

What Treatment Strategy Worked for This High-Risk Patient?

Given the patient's advanced age and the aggressive nature of her disease, doctors chose a cautious, individualized approach rather than intensive chemotherapy. She received imatinib, a targeted therapy that blocks the KIT protein, at a low dose of 100 mg daily, combined with intensive supportive care to manage her complications.

The results were encouraging but modest. The patient experienced partial recovery of her blood cell counts, and minimal residual disease assessment showed only 10 abnormal mast cells among 47,875 nucleated cells tested, indicating that the disease was substantially controlled. She remained clinically stable without progression over a follow-up period of 4 months, despite experiencing some treatment-related side effects, including upper gastrointestinal bleeding.

"This case highlights that for older patients with MCL with high-risk features and rare KIT mutations, treatment must be highly individualized. A tailored therapeutic strategy should be employed to avoid aggressive regimens without clear benefits," stated the authors.

Zhang L, Jiang L, Zhang X, Lu Y, Wang X, Authors of Frontiers in Oncology Case Report

Why Does This Case Matter for Immune Disease Diagnosis?

This case expands the clinical and molecular spectrum of mast cell leukemia within systemic mastocytosis, demonstrating that atypical immunophenotypes and rare genetic mutations can complicate recognition of the disease. Many patients with unusual presentations may be misdiagnosed or have their condition overlooked entirely.

The findings underscore a critical principle in modern medicine: precise, multimodal diagnostics are essential for accurate classification and therapeutic decision-making. A single test, such as a peripheral blood smear or basic flow cytometry, would have missed this diagnosis. Only by combining multiple diagnostic approaches could doctors identify the true nature of the disease and tailor treatment accordingly.

While low-dose imatinib may offer transient stabilization in select high-risk patients, its long-term benefit remains undetermined, warranting further study. This case reinforces that clinicians must remain vigilant for atypical presentations of rare immune disorders, particularly in elderly patients with complex medical histories, and that individualized, precision-guided therapy may offer the best outcomes when aggressive treatment carries unacceptable risks.